Results 191 to 200 of about 151,004 (296)

Thiamine Diphosphate‐Dependent Biocatalysis in the 21st Century

Chemistry – A European Journal, EarlyView.
This account summarizes the major discoveries and recent advances, highlighting the biocatalytic abilities, mechanistic studies, and feature‐based classification that are shaping emerging perspectives on thiamine diphosphate (ThDP)‐dependent catalysis.
Lucrezia Lanza, Daniela Bjarnesen, Michael Müller   +2 more
wiley   +1 more source

A programmable lipid-triggered allosteric site modulates LC3 LIR receptor binding activity. [PDF]

Nat Commun
Gahlot D, Castin J, Mathur S, Das D, Kumar A, Arun A, Gain C, Sharma M, Pal RK, Jain N, Biswal BK, Singh R, Thukral L.   +12 more
europepmc   +1 more source

Cannabinoid CB₁ allosteric ligands suppress inflammatory pain in male mice without tolerance, motor impairment, memory deficits or respiratory depression. [PDF]

Br J Pharmacol
Solomon ID, Garai S, Thakur GA, Hohmann AG.   +3 more
europepmc   +1 more source

Microtubule Destabilizing Kinesins: A Historical Perspective and Thoughts for the Future

Cytoskeleton, EarlyView.
ABSTRACT The microtubule cytoskeleton plays critical roles in multiple cellular processes such as mitotic spindle assembly and chromosome segregation. Cells contain a number of microtubule‐associated proteins that regulate microtubule dynamics both temporally and spatially in cells. The microtubule depolymerizing kinesins include members of the Kinesin‐
Claire E. Walczak
wiley   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Cenobamate use in super‐refractory status epilepticus: A report of three cases

Epileptic Disorders, EarlyView.
Abstract Objectives Super‐refractory status epilepticus (SRSE) is a neurological emergency with high morbidity and mortality. Cenobamate, a novel antiseizure medication, may be helpful in managing SRSE, but evidence is limited. Methods This retrospective case series reports the use of cenobamate as add‐on therapy in the management of three cases of ...
Marina Romozzi, Juan Luis Alcala‐Zermeno, Antonio Funcis, Federico Tosto, Marta Piccioli, Luigi Francesco Iannone, Riccardo Maviglia, Masahito Katsuki, Yasuhiko Matsumori, Paolo Calabresi, Raffaele Iorio, Catello Vollono   +11 more
wiley   +1 more source

Structural adaptation associated with signaling preference at the human Growth Hormone-Releasing Hormone Receptor. [PDF]

Protein Cell
Wang MW, Hang K, Qiu Y, Chen X, Chen Y, Huang S, Cong Z, Zhou Q.   +7 more
europepmc   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

Epilepsia, EarlyView.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

Epilepsia, EarlyView.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Kinetic Benefit(s) of Allosteric Receptor Blockade by Positive Allosteric Modulator Antagonists. [PDF]

ACS Pharmacol Transl Sci
Vauquellin G, Kenakin T.
europepmc   +1 more source